The therapy consists of a non-replicating recombinant AAV9 with a functional copy of the human SMN1 gene controlled by the CMV enhancer/chicken-actin-hybrid promoter (CB) to express SMN1 in SMA patients’ motor neurons. Here, SMN1 is linked to proximal spinal muscular atrophy.